ClinicalTrials.gg
RecruitingNCT07010237Updated Jun 8, 2025

Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia

A Phase 2 interventional study of Dose-attenuated IST and Hetrombopag in Sever Aplastic Anaemia, Elderly (People Aged 65 or More) and Immunosuppressive Treatment, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
4th of 25
65 · median 40
Started
2025
with 7 others
Phase 2
14 of 31
5 open now
Primary completion
2028-12
later than 14 of 17 live
Registered
21st of 31
by date

Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 8 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 14 of the 17 other live ones, and was the 21st registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.

Read the detailed description

Design : Prospective, single-center, single-arm, open-label Phase IIB trial.

Intervention :

P-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag : 15 mg daily. Follow-Up : Weekly for 24 weeks, with bone marrow evaluation at 24 weeks.

Inclusion Criteria :

Confirmed diagnosis of VSAA/SAA. Age ≥65 years. Completion of all screening assessments. Ability to swallow oral medication. Signed informed consent (by patient or legal guardian if patient is incapacitated).

Exclusion Criteria :

Clonal cytogenetic abnormalities (excluding isolated -Y or +8). Prior treatment with ATG/high-dose cyclophosphamide. Prior cyclosporine/tacrolimus use >12 months. Prior TPO-RA therapy >3 months. Uncontrolled malignancies or conditions contraindicating ATG. Severe organ dysfunction (e.g., creatinine ≥177 μmol/L). Investigator judgment of unsuitability.

03

Conditions studied

  • Sever Aplastic Anaemia
  • Elderly (People Aged 65 or More)
  • Immunosuppressive Treatment

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of VSAA/SAA.
  • Age ≥65 years.
  • Completion of all screening assessments.
  • Must be able to swallow tablets.
  • Signed (by patient or legal guardian if patient is incapacitated).

Exclusion criteria

Exclusion Criteria:

  • Clonal cytogenetic abnormalities (excluding isolated -Y or +8).
  • Prior treatment with ATG/high-dose cyclophosphamide.
  • Prior cyclosporine/tacrolimus use >12 months.
  • Prior TPO-RA therapy >3 months.
  • Uncontrolled or conditions contraindicating ATG.
  • Severe organ dysfunction (e.g., creatinine ≥177 μmol/L).
  • Investigator judgment of unsuitability.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    A-IST

    Porcine-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag: 15 mg daily.

    Drug: Dose-attenuated IST and Hetrombopag

Interventions

  • DrugDose-attenuated IST and Hetrombopag

    Porcine-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag: 15 mg daily for 24weeks.

06

What researchers measure

Primary outcomes

  1. Hematologic response rate at 24 weeks post-ATG treatment.

    PR+CR Partial Response (PR) : Independence from transfusions without meeting CR. No Response (NR) : Failure to achieve PR.

    Time frame: 24 weeks

Secondary outcomes

  1. Early mortality rate

    Early mortality rate within 12weeks

    Time frame: 12 weeks

  2. Complete Response

    Complete Response (CR) : HGB ≥100 g/L, PLT ≥100×10⁹/L, ANC ≥1.0×10⁹/L.

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Red Blood Cell Diseases Center
    Tianjin, Tianjin, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 46 months is below that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
Jun 8, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jul 1, 2029
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07010237
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Feb 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Jun 8, 2025

Study contacts

Jianping Li, MD
Contact
lijianping@ihcams.ac.cn
+8613820961539
Jingyu Zhao, MPH
Contact
zhaojingyu@ihcams.ac.cn
+8613752253515
Jun Shi, PhD
principal investigator · Institute of Hematology & Blood Diseases Hospital, CAMS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion